FeesSafety
Pluang+

Wix reports Q3 2026 revenue up 13% driven by Base44 growth and launches AI-powered Studio Two.

Company Fundamentals
10 Nov 2026, 08:00 WIB
GlobeNewsWire
View Source
Bullish
Wix reports Q3 2026 revenue up 13% driven by Base44 growth and launches AI-powered Studio Two.

Wix.com reported Q3 2026 revenue of $570 million, a 13% year-over-year increase, fueled by strong performance from its Base44 platform, which is nearing $250 million in annual recurring revenue. The company launched Studio Two, an advanced AI-powered design platform aimed at professional users, signaling a strategic focus on AI and openness. Despite a GAAP net loss of $13.7 million, Wix posted a non-GAAP net income of $69.3 million and expects continued growth and improved margins for Base44 in the coming quarters. Co-Founder Nir Zohar was named Co-CEO, emphasizing a leadership focus on scaling the business and advancing AI-driven product development.

Wix's Q3 2026 results provide context for technology sector activity on Pluang. For readers following technology stocks, here is Pluang's market snapshot as of Nov 10, 2026 12:11 WIB: Out of 150 priced US tech stocks, 108 rose and 42 fell. Notable movers include Bitdeer Technologies Group (BTDR) at USD 6.62 with a 10.06% increase, Applied Materials, Inc. (AMAT) at USD 366.05 up 10.02%, and BigBearai Holdings Inc (BBAI) at USD 2.44 rising 9.91%. Typical hold times range from 17 to 68 days, with buy orders dominating BTDR and AMAT.

More News

Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.

Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.

Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...

Market News
Bullish
12 minutes ago
Valneva's chikungunya vaccine IXCHIQ® shows 94% antibody persistence five years after one dose

Valneva's chikungunya vaccine IXCHIQ® shows 94% antibody persistence five years after one dose

Valneva SE reported that 94% of participants maintained a strong immune response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable antibody persistence across all age groups, including those over 65, suppor...

Market News
Bullish
5 hours ago
U.S. spot Ethereum ETFs see $184.51M outflows for third day, led by BlackRock's ETHA fund.

U.S. spot Ethereum ETFs see $184.51M outflows for third day, led by BlackRock's ETHA fund.

U.S. spot Ethereum ETFs experienced net outflows totaling $184.51 million on November 9, marking the third consecutive day of withdrawals. The outflows were mainly driven by BlackRock's ETHA fund, which lost $119.28 million, surpassing inflows to the...

Bearish
5 hours ago
U.S. spot Bitcoin ETFs see $201M net outflows, led by BlackRock's IBIT fund

U.S. spot Bitcoin ETFs see $201M net outflows, led by BlackRock's IBIT fund

U.S. spot Bitcoin ETFs experienced net outflows for the third day in a row, with $201.08 million withdrawn on November 9, 2026. BlackRock’s IBIT fund led the outflows, losing $213.23 million, while Morgan Stanley’s MSBT was the only ETF to attract ne...

Bearish
5 hours ago
Autoliv appoints Joachim Rosenberg to its Board, expanding it to 10 members.

Autoliv appoints Joachim Rosenberg to its Board, expanding it to 10 members.

Autoliv, a global leader in automotive safety systems, has appointed Joachim Rosenberg as an independent director to its Board of Directors, increasing the board size from nine to ten members. Rosenberg brings extensive experience from his 20-year ca...

Company Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App